CDSCO Medical Device Registration for Oncology: The Complete India Regulatory Guide 2026

• CDSCO Medical Device Registration For Oncology devices in India are classified under Class A to Class D — with most cancer diagnostic and therapeutic devices falling under Class C or Class D, requiring CDSCO Central License.
• CDSCO's SUGAM online portal is the mandatory submission platform for all oncology device registration applications in India as of 2026 — paper filings are no longer accepted.
• International oncology device manufacturers with FDA, CE Mark, TGA, Health Canada, or PMDA approval can apply for a clinical data waiver, significantly cutting registration time and cost.
• Registration costs for oncology devices under CDSCO range from approximately INR 50,000 for Class B devices to INR 5 lakh or more for Class D devices requiring clinical trial data.

Introduction

If you are a manufacturer, importer, or distributor planning to bring an oncology medical device to the Indian market, understanding the CDSCO medical device registration process is the single most important step in your market entry strategy. India is one of the fastest-growing medical device markets in the world, and oncology — driven by a rising cancer burden, expanding hospital infrastructure, and government-backed schemes like Ayushman Bharat — is among the most active segments.

The regulatory authority that governs this space is the Central Drugs Standard Control Organization (CDSCO), operating under India's Ministry of Health and Family Welfare. CDSCO regulates all medical devices — including oncology diagnostic systems, cancer surgical instruments, radiation therapy equipment, and IVD cancer assays — under the Medical Devices Rules, 2017 (MDR 2017), last amended in 2020.

This guide covers everything you need to know about CDSCO medical device registration for oncology in 2026 — from device classification and documentation requirements to SUGAM portal submission, timelines, costs, clinical data waivers, and the most common approval pitfalls. If you are serious about getting your cancer device approved in India, this is your starting point.

What Is CDSCO Medical Device Registration for Oncology?

CDSCO medical device registration for oncology is the formal regulatory process through which a manufacturer, importer, or authorized agent obtains a license to legally import, manufacture, or sell a cancer-related medical device in India. The process is governed by the Medical Devices Rules, 2017, notified under the Drugs and Cosmetics Act, 1940, and administered by CDSCO at the central level as well as State Licensing Authorities (SLAs) at the state level, depending on device risk classification.

All medical devices — including oncology products — that fall within the scope of India's regulated device list must be registered before they can be placed on the Indian market. Non-compliance results in seizure, import ban, and significant financial penalties. For foreign manufacturers, the entire registration process must be conducted through an India-based Authorized Indian Representative (AIR).

2026 Update: As per the latest CDSCO circular, the scope of regulated medical devices in India has been progressively expanded. If your oncology device was previously unregulated under India's older framework, it is highly advisable to verify current classification status on the CDSCO website or consult a regulatory affairs expert before assuming exemption.

CDSCO Device Classification for Oncology — Class A to Class D

Under the Medical Devices Rules, 2017, all medical devices — including oncology devices — are classified into four risk-based categories. This classification determines which regulatory authority handles the application, what documentation is required, and whether clinical data must be submitted or can be waived.

Most oncology therapeutic and diagnostic devices — including radiation systems, cancer biomarker assays, positron emission tomography (PET) components, and computer-aided detection (CAD) tools for cancer — fall under Class C or Class D. Manufacturers must ensure correct classification before beginning documentation, as incorrect classification is one of the leading causes of CDSCO registration delays.

Who Needs to Apply for CDSCO Oncology Device Registration?

Understanding who bears the registration obligation is critical before beginning the process. Under Indian law, the following parties are required to obtain CDSCO registration for oncology devices:

• Indian manufacturers: Any company manufacturing a regulated oncology device in India must obtain a manufacturing license from the State Licensing Authority (for Class A/B) or CDSCO (for Class C/D) before commercial production and sale.
• Foreign manufacturers / importers: Any foreign company wishing to import and sell an oncology device in India must appoint an Authorized Indian Representative (AIR) and obtain an import license under Form MD-14 or MD-15 depending on device class.
• Indian importers / distributors: Entities importing oncology devices on behalf of a foreign manufacturer must hold a valid import license and ensure the foreign manufacturer holds valid registration.
• Repacking / relabelling entities: Companies that repack or relabel regulated oncology devices in India are also subject to CDSCO licensing requirements.

CDSCO SUGAM Portal — How to Submit Your Oncology Device Application

All CDSCO medical device registration applications — including those for oncology devices — must be filed online through the SUGAM portal (sugam.gov.in). The portal manages the entire lifecycle of the application, from initial submission and fee payment to query responses, additional information requests, and final license issuance.

Step-by-Step SUGAM Submission Process for Oncology Devices

• Create and verify your SUGAM account: Register as a manufacturer or importer on the SUGAM portal. Foreign manufacturers must register through their AIR's account. Ensure all company details, contact information, and GST/DUNS numbers are accurate before filing.
• Select the correct application form: Use Form MD-14 for import license (Class C and D oncology devices) or Form MD-41 for manufacturing license. Selecting the wrong form results in outright rejection and restarts the clock.
• Upload the complete technical dossier: All documentation — device description, risk management file, quality management system certificates, clinical data or waiver justification, labelling, and test reports — must be uploaded in the specified PDF format. CDSCO does not accept incomplete submissions.
• Pay the prescribed government fee: Fee payment is made online through the SUGAM portal payment gateway. Government registration fees for Class C and Class D oncology devices range from INR 50,000 to INR 5,00,000 depending on device category and applicant type (Indian vs. foreign manufacturer).
• Track application status and respond to queries: CDSCO officers raise queries (Additional Information requests) through the portal. All responses must be submitted within the specified time window. Missing a query deadline results in application rejection.
• Receive Grant of Import License or Manufacturing License: Upon successful review, CDSCO issues the licence electronically through SUGAM. The licence is valid for 5 years and must be renewed before expiry.

Required Documentation for CDSCO Oncology Device Registration

The documentation requirements for CDSCO oncology device registration vary based on device classification, whether the applicant is an Indian or foreign manufacturer, and whether clinical data is being submitted or a waiver is being claimed. Below is a comprehensive checklist applicable to Class C and Class D oncology devices — the categories covering the vast majority of cancer diagnostic and therapeutic products.

Core Technical Dossier Requirements

• Device description and intended use: A detailed technical description of the oncology device, its mechanism of action, intended patient population (including cancer type and stage where relevant), and indications for use.
• Risk management file: Prepared in accordance with ISO 14971:2019. Must address oncology-specific risks including radiation exposure (for radiotherapy devices), cytotoxic drug contact (for chemotherapy delivery devices), and software failure modes (for AI-based cancer diagnostics).
• Quality Management System certificate: ISO 13485:2016 certificate from an accredited certification body. CDSCO accepts certificates issued by recognized bodies. For foreign manufacturers, the QMS certificate must be in the name of the manufacturing facility, not just the parent company.
• Performance and safety test reports: Electrical safety (IEC 60601 series), electromagnetic compatibility (IEC 60601-1-2), biocompatibility (ISO 10993 series for contact devices), sterility validation (for sterile oncology devices), and any oncology-specific performance standards applicable to your device type.
• Labelling and Instructions for Use (IFU): Must comply with CDSCO labelling requirements under Schedule V of the Medical Devices Rules, 2017. Labels must include the device name, model, manufacturer name and address, manufacturing date, shelf life (if applicable), and statutory warnings. IFU must be in English.
• Clinical data or waiver justification: For Class C and Class D oncology devices. If submitting clinical data, it must include clinical investigation reports or published peer-reviewed literature demonstrating safety and performance in the intended oncology indication. If claiming a waiver, a formal waiver application with supporting reference country approval documents must be included.
• Free Sale Certificate (FSC): For foreign manufacturers, a Certificate of Free Sale from the country of manufacture, duly notarized and apostilled, confirming the device is legally marketed in its home market.
• Authorized Indian Representative (AIR) agreement: Notarized Power of Attorney, AIR appointment letter, and AIR's Indian business registration documents.
• Post-Market Surveillance (PMS) plan: Mandatory for Class C and Class D oncology devices. Must outline the manufacturer's plan for monitoring device performance in the Indian market post-approval, including adverse event reporting procedures under CDSCO's vigilance framework.

Additional Requirements for Specific Oncology Device Categories

CDSCO Clinical Data Waiver for Oncology Devices — The Fast Track to Indian Market

One of the most strategically important provisions in India's Medical Devices Rules, 2017 for oncology device manufacturers is the clinical data waiver. For international manufacturers who have already obtained regulatory approval for their oncology device in a reference country, CDSCO may waive the requirement to conduct separate clinical investigations in India — dramatically reducing both the time and cost of registration.

Reference Countries Accepted by CDSCO for Clinical Data Waiver

To claim a clinical data waiver, the applicant must submit the following as part of the CDSCO registration application through the SUGAM portal:

• A certified copy of the reference country regulatory approval (e.g., FDA 510(k) clearance letter), apostilled or notarised as required
• A formal written justification explaining why the clinical data from the reference country is applicable to the Indian population and patient setting
• Evidence that the device is currently being sold and actively used in the reference country market
• A statement confirming the device has not been withdrawn from any market due to safety concerns
• An Indian-specific risk summary addressing any population-specific considerations — particularly relevant for oncology devices used in cancer types with different prevalence profiles in India versus Western markets

CDSCO Oncology Device Registration — Timelines and Costs in 2026

One of the first questions every oncology device manufacturer asks is: how long will this take, and what will it cost? Here is a realistic breakdown based on current CDSCO processing realities in 2026.

These timelines assume a complete and well-prepared application at the time of submission. Each CDSCO query cycle — where CDSCO raises an Additional Information (AI) request and the applicant must respond — typically adds 2–4 months to the timeline. Complex Class D oncology devices have seen as many as three or four query cycles before final approval. Working with an experienced CDSCO regulatory consultant who specializes in oncology submissions is one of the most effective ways to reduce these delays.

Government Registration Fees — CDSCO 2026

CDSCO Registration for Specific Oncology Device Categories

Oncology is a broad clinical field, and the regulatory requirements vary meaningfully across different device categories. Here is a focused breakdown of what CDSCO expects for the most commonly registered cancer device types in India.

1. Radiation Oncology Devices (LINAC, Brachytherapy, Cobalt-60 Systems)

Radiation therapy devices are among the most tightly regulated oncology products in India. In addition to CDSCO registration under Class D, all radiation-emitting devices require separate clearance from the Atomic Energy Regulatory Board (AERB) under the Atomic Energy (Radiation Protection) Rules, 2004. AERB clearance must be obtained before the device can be installed or operated at any Indian healthcare facility.

Manufacturers must ensure that both the CDSCO import license and the AERB equipment approval are coordinated, as hospitals purchasing these devices require both certificates before commissioning. AERB site approvals are also required for each installation, which means the regulatory burden extends beyond the manufacturer to the end-user facility.

2. Oncology In Vitro Diagnostic (IVD) Devices

Cancer IVDs — including HER2 amplification testing kits, BRCA mutation assays, liquid biopsy platforms, circulating tumour DNA (ctDNA) detection systems, and PSA immunoassay kits — are regulated as Class C or Class D devices under the Medical Devices Rules, 2017, scheduled under the notified IVD list.

For oncology IVDs, CDSCO requires detailed analytical performance data including sensitivity, specificity, limit of detection, precision, and interference studies. For companion diagnostics tied to specific oncology drugs, the IVD registration must reference the associated drug's approval. CDSCO expects performance data from studies conducted on or validated against Indian patient samples for novel oncology IVDs — a requirement that catches many international manufacturers off guard.

3. AI-Powered Oncology Diagnostic Software (SaMD)

Artificial intelligence-based cancer diagnostic tools — such as AI-assisted mammography CADe systems, AI lung nodule detection software, AI pathology slide analysis platforms, and AI-based colonoscopy detection tools — are classified as Software as a Medical Device (SaMD) and fall under CDSCO regulation when they meet the definition of a medical device under Indian law.

CDSCO's 2023 guidance on SaMD (aligned with IMDRF SaMD framework) requires manufacturers to submit IEC 62304 software lifecycle documentation, algorithm validation reports, cybersecurity risk analysis, and — for AI oncology tools specifically — evidence that the algorithm's performance has been validated on data representative of Indian patients. This last requirement is a significant consideration for international AI oncology products developed and trained primarily on Western datasets.

4. Oncology Surgical and Interventional Devices

Minimally invasive oncology devices — including tumour ablation probes (radiofrequency, microwave, cryoablation), laparoscopic oncology instruments, endoscopic resection devices, and robotic surgery systems used in cancer procedures — are classified as Class B to Class D depending on their risk profile and contact nature.

For Class C and Class D surgical oncology devices, CDSCO requires biocompatibility testing per ISO 10993 (particularly for devices that contact tissue or blood), sterility validation for sterile devices, and electrical safety data per IEC 60601-1. Robotic surgery systems carry the most demanding documentation burden and typically require clinical data from peer-reviewed literature or clinical investigations specifically in oncology surgical settings.

Common Mistakes That Delay CDSCO Oncology Device Approval

Based on real-world experience with CDSCO submissions across the oncology spectrum, here are the most consistent errors that result in query letters, application rejections, or multi-year delays.

• Incorrect device classification: Classifying a Class D oncology device as Class C to reduce regulatory burden is a common and costly error. CDSCO officers scrutinize the risk justification carefully — especially for implantable and radiation-emitting oncology devices. Incorrect classification leads to rejection and restart.
• Appointing an under-resourced AIR: Foreign oncology device manufacturers sometimes appoint AIRs based purely on cost rather than competence. An AIR with no CDSCO oncology experience will be unable to respond effectively to technical queries, delaying approvals significantly.
• Incomplete clinical data waiver package: Submitting only the reference country approval letter without the supporting justification, active marketing evidence, and population-specific risk summary is the most common reason CDSCO rejects clinical data waiver claims for oncology devices.
• Non-compliant labelling and IFU: Labels that do not include all Schedule V mandatory elements, or IFUs that describe oncology indications not covered by the reference country approval, are consistent sources of CDSCO queries.
• Missing AERB coordination for radiation oncology devices: Filing CDSCO registration for a linear accelerator or brachytherapy system without an AERB strategy in place leads to a situation where the device is CDSCO-approved but cannot be legally operated in India. Both approvals must be planned together.
• Outdated ISO 13485 certificate: CDSCO routinely rejects applications where the QMS certificate has expired or is nearing expiry (within 3 months). The certificate must remain valid throughout the entire review period.
• Failure to address Indian population-specific considerations: For AI oncology devices and oncology IVDs, CDSCO expects some acknowledgement of performance data or validation in the Indian patient population. Submitting data exclusively from Western patient cohorts without addressing Indian demographic applicability is a growing reason for AI queries in 2026.

Conclusion

CDSCO medical device registration for oncology in India is a structured, rules-based process — and in 2026, it is more rigorous and more consequential than at any point in the past decade. The Indian cancer device market is growing fast, the regulatory framework is maturing rapidly, and CDSCO's expectations for documentation quality, clinical evidence, and post-market accountability are rising in step.

The manufacturers and importers who succeed in this environment are the ones who take classification seriously from day one, who invest in qualified documentation and experienced AIRs, and who approach CDSCO registration as a long-term market access strategy rather than a one-time filing exercise. The clinical data waiver pathway remains one of India's most valuable market entry tools for internationally approved oncology devices — but it must be used correctly to deliver its full benefit.

Whether you are registering a radiation therapy system, an AI-based cancer diagnostic tool, an oncology IVD, or a minimally invasive cancer surgical device, the regulatory pathway to the Indian market is navigable. The requirements are clear. The process is defined. With the right preparation and the right regulatory partner, CDSCO approval for your oncology device is within reach.

Frequently Asked Questions